GenScript Biotech 2017 Annual Result Presentation April 12, 2018 - PowerPoint PPT Presentation

GenScript Biotech 2017 Annual Result Presentation April 12, 2018

Disclaimer NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, JAPAN OR ANY JURISDICTION WHERE SUCH DISTRIBUTION IS NOT PERMITTED UNDER THE LAW OF THAT JURISDICTION. This document has been prepared by Genscript Biotech Corporation (the “Company”) for a limited number of recipients and for i nformation purposes only. The information relating to the Company, its subsidiaries and affiliates, and their respective businesses and assets contained in this document has not been independently verified. This document does not purport to provide a complete description of the matters to which it relates. Some of the information is still in draft form and will only be finalized at the time of publication of the relevant prospectuses or offering circulars of the Company. No reliance shall be made in relation to the information contained in this document. No representation, warranty or undertaking, express or implied, is or will be made in, or in relation to, and no responsibility or liability (including, without limitation, any liability in negligence) is or will be accepted by the Company, Sole Sponsor, Joint Global Coordinators, Joint Bookrunners and Joint Lead Managers, or any of their shareholders, directors, officers, employees, affiliates, advisors or representatives as to, or in relation to, this document or the accuracy, fairness, reasonableness, correctness, or completeness of the information or opinions contained herein or any other information or opinions, whether written or oral, made available to any interested party or its advisors and any liability for any loss howsoever arising from any use of this document or its contents or otherwise arising in connection with this document therefore is hereby expressly disclaimed. The information contained in this document should be considered in the context of the circumstances prevailing at the time and is subject to change without notice. By preparing this document, none of the Company, Sole Sponsor, Joint Global Coordinators, Joint Bookrunners and Joint Lead Managers, or any of their shareholders, directors, officers, employees, affiliates, advisors or representatives undertakes any obligation to provide the recipient with access to any additional information or to update this presentation or any additional information or to correct any inaccuracies in any such information which may become apparent. This document contains statements that reflect the Company’s current beliefs and expectations about the future as of the resp ective dates indicated herein. These forward-looking statements are based on a number of assumptions about the Company’s operations, information currently available to the Company, and factors beyond the Company’s control and are subjec t to significant risks and uncertainties, and, accordingly, actual results may differ materially from these forward- looking statements. The Company undertakes no obligation to update these forward-looking statements for events or circumstances that occur subsequent to such dates. This document does not constitute or form part of, and should not be construed as, an offer to sell or issue or a solicitation of an offer to purchase or subscribe for any securities of the Company nor shall there be any sale of such securities in any state or country in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or country. Public offering of securities to be made in the United States must be made by means of a prospectus that may be obtained from the issuer or the selling security holder and that contains detailed information about the issuer, its management and financial statements. No securities of the Company have been, or will be, registered under the US Securities Act of 1933 , as amended (the “US Securities Act”) or the securities laws of any state or other jurisdiction of the United States and may not be offered or sold within the United States, except pursuant to a registered offering in compliance with or pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the US Securities Act and the applicable securities laws of any state or other jurisdiction of the United States. In Hong Kong, no securities of the Company may be offered to the public unless a prospectus in connection with the offering for sale or subscription of such securities has been authorized by The Stock Exchange of Hong Kong Limited for registration by the Registrar of Companies in Hong Kong under the provisions of the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap.32 of the Laws of Hong Kong), and has been so registered. No part of this document shall form the basis of or be relied upon in connection with any contract, commitment or investment decision in relation thereto. Any decision to purchase any securities of the Company in any offering for sale, distribution or subscription (as the case may be) in the United States, Hong Kong or anywhere else should be made solely on the basis of information contained in the relevant prospectuses or offering circulars of the Company which will be published in due course. The recipients and readers of this document should not construe the contents of this document as legal, tax, accounting or investment advice and should consult their own financial, tax, accounting or legal advisors or other consultants in case of doubt. This document, and any further information made available to you, are highly confidential and should not be distributed, published or reproduced (in whole or in part) or disclosed to any other person, directly or indirectly. This document must not be copied, reproduced, distributed or passed, in whole or in part, to any other person, directly or indirectly, at any time, by any medium, in any form, for any purpose without the prior written consent of the Company, Sole Sponsor, Joint Global Coordinators, Joint Bookrunners and Joint Lead Managers. Unauthorized copying or reproduction, or redistribution of this document of any information contained herein to any person, could result in material delay to, or otherwise prejudice the success of the global offering of the Company. No part of this document may be distributed, reproduced, taken or transmitted into the United States, Canada or Japan, or to any resident thereof. You acknowledge and represent to the Company, Sole Sponsor, Joint Global Coordinators, Joint Bookrunners and Joint Lead Managers that you are a professional investor, have the knowledge, experience and capability to conduct your own assessment of the Company and its securities and that you have conducted and will conduct your own investigation with respect to the Company and its securities and have obtained or will obtain your own independent advice relating to any investment in the securities of the Company. By accepting delivery of this document or the information contained herein, you are deemed to represent to the Company, Sole Sponsor, Joint Global Coordinators, Joint Bookrunners and Joint Lead Managers, and their shareholders, directors, officers, employees, agents, affiliates, advisors and representatives, that you are and any person you are representing, if any, a person outside the United States within the meaning of Regulation S under the US Securities Act, or a professional investor within a category of person described in the Securities and Futures (Professional Investor) Rules (Chapter 571D of the Laws of Hong Kong). By accepting delivery of this document or the information contained herein, you are agreeing that (i) you have read and agree to comply with the requirements of this disclaimer; (ii) you will maintain absolute confidentiality regarding this document and the information contained herein; and (iii) you will not make direct contact with (a) the Company’s customers, partners o r subcontractors; (b) any governmental, administrative or regulatory bodies which supervise or regulate the Company; or (c) employees of the Company in order to seek non publicly available information of the Company. 2

Company Overview Background of the Industry Business and Finance Cell Therapy Investment Highlights

Mission Make People and Nature Healthier through Biotechnology Make Research Easy Make the Best Enzyme Bring Miracles to Life 4

Business Blueprint 5

History & Milestone • New Nanjing research and production • Listed in HKEX facility opened (Stock code:1548) 2017 • Selected as the only commercial entity • Established to participate in the Synthetic Yeast presence in Europe Genome Sc2.0 Project • Established subsidiary in Japan 2016 • Employee headcount reached 1,000 • Legend and Jassen 2015 entered into 2014 collaboration in related to CAR-T product . • CFDA accepted the 2013 • CRO Leadership award • Introduced application for 2011 • Merged Nornoon investigational new drug • Developed Gene 2009 by Legend Company Synthesis • Acquired 100% of GenPlusTM next • Invested in Zhenjiang 2008 Service generation gene 2004 issued share of • Launched eStain synthesis technology 2003 CustomArray • Developed the 2002 L1 ,an innovative • KPCB / TBIG • Introduced Custom • Launched industrial-leading instrument • Founded • Launched new and Healthcare composite Protein and the investment glucosydase product Antibody Service industrial in New stable cell lines for starch processing • Established synthetic Jersey industry biology • Developed the half-life research and product manufacturing segment extension technology center in Nanjing , for single domain China antibody drugs 6